Literature DB >> 21225196

Cryptococcus neoformans var. grubii - Pathogenicity of environmental isolates correlated to virulence factors, susceptibility to fluconazole and molecular profile.

Reginaldo S Pedroso1, Marco As Lavrador, Joseane C Ferreira, Regina C Candido, Claudia Ml Maffei.   

Abstract

The pathogenicity of Cryptococcus neoformans is heterogeneous and is associated with the expression of virulence factors. This study aimed to correlate the pathogenicity of C. neoformans var. grubii in BALB/c mice with in vitro virulence factors, fluconazole minimal inhibitory concentrations (MICs) and molecular profiles, before and after animal passage. Ten environmental isolates and one ATCC strain of C. neoformans var. grubii mating type α were evaluated. Most isolates (91%) killed 50% or more of the infected animals by day 24 postinfection and were recovered from the lungs and brains of surviving animals on days 7 and 14 postinfection. The burden of yeast in the lungs was more variable than that in the brain. The differences in the expression of virulence factors (growth at 37ºC, presence and size of the capsule and production of melanin, urease, proteinase and phospholipase) by most isolates pre and postpassage in animals were not statistically significant. The fluconazole MICs in postpassaged lines differed by a one-dilution from the MIC of the corresponding prepassaged line for six isolates. Using molecular typing [polymerase chain reaction-fingerprinting with (GACA)4 and M13], eight isolates were identified as VNI and three as VNII. We concluded that different isolates with the same molecular and phenotypic profiles, including isolates that are markedly hypervirulent, span a wide range of virulence and there were no changes in virulence factors in the postpassaged lines when compared with the corresponding nonpassaged lines.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21225196     DOI: 10.1590/s0074-02762010000800008

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  6 in total

1.  Population genetic analyses reveal the African origin and strain variation of Cryptococcus neoformans var. grubii.

Authors:  Anastasia P Litvintseva; Thomas G Mitchell
Journal:  PLoS Pathog       Date:  2012-02-23       Impact factor: 6.823

2.  The epidemiology of cryptococcosis and the characterization of Cryptococcus neoformans isolated in a Brazilian University Hospital.

Authors:  Paula Augusta Dias Fogaça de Aguiar; Reginaldo Dos Santos Pedroso; Aércio Sebastião Borges; Tomaz de Aquino Moreira; Lúcio Borges de Araújo; Denise Von Dolinger de Brito Röder
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2017-04-13       Impact factor: 1.846

3.  In Vitro Antifungal Susceptibility of Environmental Isolates of Cryptococcus spp. from the West Region of Cameroon.

Authors:  William Dongmo; Frederick Kechia; Roland Tchuenguem; Claude Nangwat; Iwewe Yves; Jules-Roger Kuiate; Jean Paul Dzoyem
Journal:  Ethiop J Health Sci       Date:  2016-11

4.  Genotypic analysis of clinical and environmental Cryptococcus neoformans isolates from Brazil reveals the presence of VNB isolates and a correlation with biological factors.

Authors:  Leonardo Euripedes Andrade-Silva; Kennio Ferreira-Paim; Thatiana Bragine Ferreira; Anderson Vilas-Boas; Delio José Mora; Verônica Morais Manzato; Fernanda Machado Fonseca; Kelli Buosi; Juliana Andrade-Silva; Bruno da Silva Prudente; Natalia Evelyn Araujo; Helioswilton Sales-Campos; Marcus Vinicius da Silva; Virmondes Rodrigues Júnior; Wieland Meyer; Mario Léon Silva-Vergara
Journal:  PLoS One       Date:  2018-03-05       Impact factor: 3.240

5.  Microevolution during serial mouse passage demonstrates FRE3 as a virulence adaptation gene in Cryptococcus neoformans.

Authors:  Guowu Hu; Shu Hui Chen; Jin Qiu; John E Bennett; Timothy G Myers; Peter R Williamson
Journal:  mBio       Date:  2014-04-01       Impact factor: 7.867

Review 6.  Cryptococcus-Epithelial Interactions.

Authors:  Leanne M Taylor-Smith
Journal:  J Fungi (Basel)       Date:  2017-10-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.